- Email: [email protected]
Second-Line Therapy In Patients with Locally Advanced or Metastatic Urothelial Cancer: A Systematic Literature Review
A414
VA L U E I N H E A LT H 2 0 ( 2 0 1 7 ) A 3 9 9 – A 8 1 1
rates. Results: Data were available from 209 CCGs. The incidences of breast and lung cancers were positively correlated with IMD score (R= 0.39 [p< 0.001] and R= 0.78 [p< 0.001], respectively). Early-stage detection was also positively correlated with IMD score for all cancer types (R= 0.19 [p< 0.01], R= 0.18 [p< 0.01] and R= 0.25 [p< 0.001] for breast, colorectal and lung cancers, respectively). While colorectal cancer-related under-75 mortality was positively correlated with IMD score (R= 0.28 [p< 0.001]), no correlation was observed between breast and lung cancer mortality and IMD score (R= 0.05 [p= 0.50] and R= 0.05 [p= 0.50], respectively). There was also no correlation between IMD score and colorectal cancer incidence (R= 0.08 [p= 0.27]) or one-year survival for lung cancer (R= 0.02 [P= 0.73]). However, one-year survival was negatively correlated with IMD score for breast and colorectal cancers (R= 0.37 [p< 0.001] and R= 0.46 [P< 0.001], respectively). Conclusions: Despite the well-established link between deprivation and cancer incidence and poorer outcomes, CCG-level data do not always reflect this. Of note was the positive correlation between deprivation and early detection, which is unexpected given the lower uptake of cancer screening in more deprived areas. These data suggest that other factors exist within CCG populations that may affect outcomes.
for Effectiveness and Economics (MORE²) Registry payer claims and remittance dataset. HRU was assessed from the date of CLL onset to the date of the last administrative claim and reported as per-patient per-month (PPPM). Results: Among the 2,342 CLL patients, 295 patients were treated with ibrutinib while 2,047 patients were not. Median age for all patients was 65 years; median follow-up was 359.87 days. More patients on ibrutinib were men (68.5% vs 57.8%, p-value < 0.001), had commercial payer (39.1% vs 27.6%, p-value < 0.001), lower inpatient costs (mean $813 vs $1,704, p-value < 0.001), mean emergency room (ER) costs ($101 vs $177, p-value 0.007), and mean outpatient visits (3.74 vs 4.81, p-value 0.002) respectively. No statistically significant differences across length of stay, ER visits, office utilization and outpatient costs were observed. Conclusions: CLL patients on experienced significant decreases in both inpatient and ER related costs compared to CLL patients not on ibrutinib. Longer follow up is needed to examine how these lower costs relate to outcomes.
PCN14 Network Meta-Analysis of Treatments For Unresectable Hepatocellular Carcinoma
Mateos M1, Raab MS2, Cavo M3, Gonzalez-McQuire S4, Fink L5, Schoen P4, Biedermann P4 Hospital of Salamanca, Salamanca, Spain, 2Heidelberg University Hospital, Heidelberg, Germany, 3Bologna University School of Medicine, Bologna, Italy, 4Amgen (Europe) GmbH, Zug, Switzerland, 5Kantar Health, Paris, France
Tremblay G1, Meier G2, Copher R2, Misurski D2, Pan J2, Baig M2, Tamai T2, Kraljevic S3, Shor A1, Forsythe A1 1Purple Squirrel Economics, New York, NY, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Eisai Co., Ltd., Hatfield, UK
Objectives: This study aimed to synthetize efficacy evidence via a systematic literature review and meta-analysis to enable the comparison of both lenvatinib (LEN) and sorafenib (SOR) to placebo in unresectable hepatocellular (uHCC). Methods: EMBASE®, MEDLINE®, MEDLINE® in-process and Cochrane databases were systematically searched through February 2017 for relevant RCTs in 1L uHCC. The search produced prior SOR randomized controlled trials (RCT) conducted versus placebo. Data from a recent phase 3 randomized RCT in which LEN demonstrated significantly better progression free survival (PFS) versus SOR in treatment naive (1L) uHCC patients was also included. A conventional network meta-analysis (NMA) based on PFS and overall survival (OS) was performed using a frequentist random effect NMA programmed in R-3.3.1. PBO was used as the reference treatment. Results: Three studies met inclusion criteria: the recently completed LEN vs SOR study: (N= 954) and two RCTs comparing SOR to PBO: (1) Llovet 2008 (N= 602) and (2) Cheng 2009 (N= 226). The RCTs were generally comparable with some variability in patient baseline characteristics: age (63, 66, 61), male% (84, 87, 85), ECOG 0-1% (100, 93, 95), Child–Pugh class A% (99, 97, 97) and prior hepatitis B/C% (50/23, 19/28, 73/8), in LEN vs SOR, SOR vs PBO(1) and SOR vs PBO(2), respectively. In the NMA versus PBO, LEN and SOR yielded indirect HRs of 0.38 and 0.58 for PFS, and 0.63 and 0.69 for OS, respectively. Using LEN as a common comparator, SOR and PBO yielded indirect HRs of 1.52 and 2.63 for PFS, and 1.09 and 1.58 for OS, respectively. Conclusions: Our NMA demonstrated that for 1L uHCC, both LEN and SOR demonstrated significantly better PFS vs. PBO: a 62% progression risk reduction for LEN versus 42% for SOR. PCN15 Second-Line Therapy In Patients with Locally Advanced or Metastatic Urothelial Cancer: A Systematic Literature Review
PCN17 Newly Diagnosed Multiple Myeloma (NDMM) Patient Profiles; Findings From An Observational Chart Review In France, Germany, Italy, Spain And The United Kingdom 1University
Objectives: To describe the characteristics of, and treatment outcomes in patients with specific profiles in the real-world NDMM setting. Methods: The data presented were derived from a 2016 retrospective chart analysis of 813 patients whose disease had progressed after first line (1L). Patient profiles were constructed based on stem-cell transplant (SCT) eligibility, agents used in 1L, and time to progression (TTP). All analyses were descriptive. Results: Of the 813 patients, 31% received a SCT and a bortezomib-based regimen (V). Of the 496 (61%) patients who did not receive a SCT, 71% received V, 22% received immunomodulator-based regimens (IMiD) and 7% received other regimens. Patients were then stratified by TTP (early [< 12 months] vs late [≥ 12months]). Five profiles were identified accounting for 88% of the patients included. Profile 1a (P1a): SCT, V and late progression (26%); P1b: SCT, V and early progression (6%); P2a: non-SCT, V and late progression (26%); P2b: nonSCT, V and early progression (18%), and P3: non-SCT and IMiD (13%). The median TPP and complete response rates for profiles P1a, P1b, P2a, P2b and P3 were: 33.5 months and 51%; 10 months and 16%; 24 months and 26%; 6 months and 5%; and 17 months and 24%, respectively. The proportion of patients with revised International Staging System stage III disease and the proportion of patients assessed for cytogenetic abnormalities with high-risk cytogenetics was higher in profile P1b than P1a (42% vs 22% and 25% vs 15%, respectively) and in profile P2b than P2a (46% vs 35% and 31% vs 19%, respectively). These differences may explain the differences observed in treatment outcomes. Conclusions: Achieving a prolonged TPP for all patients with NDMM continues to be a challenge. Understanding why patients progress early may inform subsequent treatment decisions and improve outcomes for patients with MM. PCN18 Matching-Adjusted Indirect Comparison (MAIC) Of Crizotinib With Standard of Care In Progressed Nsclc ALK+ Patients Based On RealWorld Evidence (RWE) And Clinical Trial Data In The Czech Republic Pasztor B1, Losenicky L2, Mazan P2, Duba J1, Kolek M1 Consulting s.r.o., Prague 9, Czech Republic, 2Pfizer PFE, spol. s r.o., Prague 5, Czech Republic
Bharmal M1, Guenther S1, Rosen G2, Kearney M1, Phatak H2, Kempel-Waibel A1 1Merck KGaA, Darmstadt, Germany, 2EMD Serono, Billerica, MA, USA
1OAKS
Objectives: Conduct a systematic literature review (SLR) of studies assessing clinical outcomes associated with pharmacological interventions in patients with locally advanced or metastatic urothelial cancer (UC) who have progressed during or after first line platinum-based chemotherapy. Methods: Medline, EMBASE, and conference proceedings databases were searched (2001 – 2017) to capture overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS) of systemic second-line therapy. 244 articles met the predefined inclusion criteria. Review of the 76 articles relating to second-line resulted in final data extraction from four randomized controlled clinical trials (RCTs) and thirty-eight single arm studies. Results: ORR with cisplatin- and carboplatin-based regimens, vinflunine, and immuno-oncology therapies (IOs) (either single or combination regimens) ranged from 8% to 50% in RCTs and from 6% to 60% in single arm studies. Median PFS with chemotherapy ranged from 3.3 to 4.0 months in RCTs (n= 2), from 1.4 to 6.0 (n= 15) in single arm studies, and from 1.1 to 4.1 (n= 5) with IOs. Median OS with chemotherapy ranged from 5.3 to 13.6 months (n= 23) and from 7.0 to 14.1 months (n= 7) with IOs (OS from many IO studies not estimated or reported due to limited follow up). Median DOR ranged from 3.9 to 9.1 months (n= 16) with chemotherapy regimens, and was not estimable in IO studies (n= 7), with > 80% of responders having responses lasting ≥ 6 months. Conclusions: There was a large variability in outcomes observed by regimen, patient population and study design. The findings of this SLR suggest a high unmet need still exists for patients who have failed or progressed after first-line treatment. This highlights the need for new treatment options that can induce durable responses in these patients. Recently approved IOs seem promising for a patient population with historically limited treatment options.
Objectives: Non-small-cell-lung-carcinoma (NSCLC) markedly shortens and deteriorates life of patients. The aim of this analysis was to compare the relative effectiveness of crizotinib in progressed NSCLC ALK+ patients to Czech standard of care based on RWE and clinical trial data while adjusting for patients’ characteristic differences. Methods: Patient characteristics and outcomes data were taken from RWE (NSCLC Registry TULUNG and Registry of Highly Innovative Drug VILP) in the Czech Republic and the PROFILE 1007 clinical trial. Patient-level data were available for crizotinib RWE only. Differences in patients’ characteristics in the crizotinib and pemetrexed arms were thus adjusted by MAIC approach. Age, sex, ECOG, smoking status, stage and histology types were included in the matching analysis. After matching, median overall survival (OS) and progression free survival (PFS) were estimated. Results: There were 51 crizotinib patients in the Czech RWE arm receiving 2nd or later line crizotinib. Median follow-up of crizotinib RWE patients was 11,5 months. After matching, the patients’ characteristics were comparable. Naïve comparison of PFS and OS resulted in medians 5,8 and 15,3 months for crizotinib from RWE, 3,1 and 9,5 months for pemetrexed from RWE and 4,2 and 22,8 for pemetrexed from PROFILE 1007. After matching, the median PFS and OS of crizotinib from RWE changed to 4,8 and 14,2 months when adjusted to pemetrexed RWE and 6,2 and 27,2 months when adjusted to pemetrexed PROFILE 1007 data. Crizotinib increased PFS by 54% and 47% and OS by 49% and 19% when compared to pemetrexed RWE and pemetrexed PROFILE 1007 data, respectively. Conclusions: Treatment of progressed ALK+ NSCLC with crizotinib is associated with major prolongation of PFS and OS compared to pemetrexed in the Czech real-world setting after adjusting for the patients’ characteristic differences.
PCN16 Comparative Study Of Healthcare Resource Utilization (HRU) Outcomes Between Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Versus Non-Ibrutinib Treated Patients Nero D1, Chung J1, Kish J1, Nabhan C2 1Cardinal Health Specialty Solutions, Dallas, TX, USA, 2Cardinal Health, Dublin, OH, USA
Objectives: Ibrutinib is a novel targeted oral therapy approved for CLL. We aimed to compare real-world HRU of ibrutinib-treated CLL patients with others not on ibrutinib. Methods: Newly diagnosed CLL patients initiating therapy between 01/01/2014-09/30/2016 were selected from the Inovalon Medical Outcomes Research
PCN19 Estimation of The Health Benefit Associated With A Potential Denosumab-Induced Extension of Progression Free Survival In Multiple Myeloma Patients Sabatelli L, Jamotte A, Giannopoulou C, Intorcia M Amgen GmbH, Zug, Switzerland
Objectives: The efficacy of Denosumab in the prevention of skeletal-related events in multiple myeloma (MM) patients, and its non-inferiority to Zoledronic Acid, was demonstrated in a randomized, double blind phase 3 trial (IMW 2017 and ASCO 2017). Preliminary analyses of trial survival data suggested that patients treated with Denosumab may have a longer progression free survival (PFS) compared to
VA L U E I N H E A LT H 2 0 ( 2 0 1 7 ) A 3 9 9 – A 8 1 1
rates. Results: Data were available from 209 CCGs. The incidences of breast and lung cancers were positively correlated with IMD score (R= 0.39 [p< 0.001] and R= 0.78 [p< 0.001], respectively). Early-stage detection was also positively correlated with IMD score for all cancer types (R= 0.19 [p< 0.01], R= 0.18 [p< 0.01] and R= 0.25 [p< 0.001] for breast, colorectal and lung cancers, respectively). While colorectal cancer-related under-75 mortality was positively correlated with IMD score (R= 0.28 [p< 0.001]), no correlation was observed between breast and lung cancer mortality and IMD score (R= 0.05 [p= 0.50] and R= 0.05 [p= 0.50], respectively). There was also no correlation between IMD score and colorectal cancer incidence (R= 0.08 [p= 0.27]) or one-year survival for lung cancer (R= 0.02 [P= 0.73]). However, one-year survival was negatively correlated with IMD score for breast and colorectal cancers (R= 0.37 [p< 0.001] and R= 0.46 [P< 0.001], respectively). Conclusions: Despite the well-established link between deprivation and cancer incidence and poorer outcomes, CCG-level data do not always reflect this. Of note was the positive correlation between deprivation and early detection, which is unexpected given the lower uptake of cancer screening in more deprived areas. These data suggest that other factors exist within CCG populations that may affect outcomes.
for Effectiveness and Economics (MORE²) Registry payer claims and remittance dataset. HRU was assessed from the date of CLL onset to the date of the last administrative claim and reported as per-patient per-month (PPPM). Results: Among the 2,342 CLL patients, 295 patients were treated with ibrutinib while 2,047 patients were not. Median age for all patients was 65 years; median follow-up was 359.87 days. More patients on ibrutinib were men (68.5% vs 57.8%, p-value < 0.001), had commercial payer (39.1% vs 27.6%, p-value < 0.001), lower inpatient costs (mean $813 vs $1,704, p-value < 0.001), mean emergency room (ER) costs ($101 vs $177, p-value 0.007), and mean outpatient visits (3.74 vs 4.81, p-value 0.002) respectively. No statistically significant differences across length of stay, ER visits, office utilization and outpatient costs were observed. Conclusions: CLL patients on experienced significant decreases in both inpatient and ER related costs compared to CLL patients not on ibrutinib. Longer follow up is needed to examine how these lower costs relate to outcomes.
PCN14 Network Meta-Analysis of Treatments For Unresectable Hepatocellular Carcinoma
Mateos M1, Raab MS2, Cavo M3, Gonzalez-McQuire S4, Fink L5, Schoen P4, Biedermann P4 Hospital of Salamanca, Salamanca, Spain, 2Heidelberg University Hospital, Heidelberg, Germany, 3Bologna University School of Medicine, Bologna, Italy, 4Amgen (Europe) GmbH, Zug, Switzerland, 5Kantar Health, Paris, France
Tremblay G1, Meier G2, Copher R2, Misurski D2, Pan J2, Baig M2, Tamai T2, Kraljevic S3, Shor A1, Forsythe A1 1Purple Squirrel Economics, New York, NY, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Eisai Co., Ltd., Hatfield, UK
Objectives: This study aimed to synthetize efficacy evidence via a systematic literature review and meta-analysis to enable the comparison of both lenvatinib (LEN) and sorafenib (SOR) to placebo in unresectable hepatocellular (uHCC). Methods: EMBASE®, MEDLINE®, MEDLINE® in-process and Cochrane databases were systematically searched through February 2017 for relevant RCTs in 1L uHCC. The search produced prior SOR randomized controlled trials (RCT) conducted versus placebo. Data from a recent phase 3 randomized RCT in which LEN demonstrated significantly better progression free survival (PFS) versus SOR in treatment naive (1L) uHCC patients was also included. A conventional network meta-analysis (NMA) based on PFS and overall survival (OS) was performed using a frequentist random effect NMA programmed in R-3.3.1. PBO was used as the reference treatment. Results: Three studies met inclusion criteria: the recently completed LEN vs SOR study: (N= 954) and two RCTs comparing SOR to PBO: (1) Llovet 2008 (N= 602) and (2) Cheng 2009 (N= 226). The RCTs were generally comparable with some variability in patient baseline characteristics: age (63, 66, 61), male% (84, 87, 85), ECOG 0-1% (100, 93, 95), Child–Pugh class A% (99, 97, 97) and prior hepatitis B/C% (50/23, 19/28, 73/8), in LEN vs SOR, SOR vs PBO(1) and SOR vs PBO(2), respectively. In the NMA versus PBO, LEN and SOR yielded indirect HRs of 0.38 and 0.58 for PFS, and 0.63 and 0.69 for OS, respectively. Using LEN as a common comparator, SOR and PBO yielded indirect HRs of 1.52 and 2.63 for PFS, and 1.09 and 1.58 for OS, respectively. Conclusions: Our NMA demonstrated that for 1L uHCC, both LEN and SOR demonstrated significantly better PFS vs. PBO: a 62% progression risk reduction for LEN versus 42% for SOR. PCN15 Second-Line Therapy In Patients with Locally Advanced or Metastatic Urothelial Cancer: A Systematic Literature Review
PCN17 Newly Diagnosed Multiple Myeloma (NDMM) Patient Profiles; Findings From An Observational Chart Review In France, Germany, Italy, Spain And The United Kingdom 1University
Objectives: To describe the characteristics of, and treatment outcomes in patients with specific profiles in the real-world NDMM setting. Methods: The data presented were derived from a 2016 retrospective chart analysis of 813 patients whose disease had progressed after first line (1L). Patient profiles were constructed based on stem-cell transplant (SCT) eligibility, agents used in 1L, and time to progression (TTP). All analyses were descriptive. Results: Of the 813 patients, 31% received a SCT and a bortezomib-based regimen (V). Of the 496 (61%) patients who did not receive a SCT, 71% received V, 22% received immunomodulator-based regimens (IMiD) and 7% received other regimens. Patients were then stratified by TTP (early [< 12 months] vs late [≥ 12months]). Five profiles were identified accounting for 88% of the patients included. Profile 1a (P1a): SCT, V and late progression (26%); P1b: SCT, V and early progression (6%); P2a: non-SCT, V and late progression (26%); P2b: nonSCT, V and early progression (18%), and P3: non-SCT and IMiD (13%). The median TPP and complete response rates for profiles P1a, P1b, P2a, P2b and P3 were: 33.5 months and 51%; 10 months and 16%; 24 months and 26%; 6 months and 5%; and 17 months and 24%, respectively. The proportion of patients with revised International Staging System stage III disease and the proportion of patients assessed for cytogenetic abnormalities with high-risk cytogenetics was higher in profile P1b than P1a (42% vs 22% and 25% vs 15%, respectively) and in profile P2b than P2a (46% vs 35% and 31% vs 19%, respectively). These differences may explain the differences observed in treatment outcomes. Conclusions: Achieving a prolonged TPP for all patients with NDMM continues to be a challenge. Understanding why patients progress early may inform subsequent treatment decisions and improve outcomes for patients with MM. PCN18 Matching-Adjusted Indirect Comparison (MAIC) Of Crizotinib With Standard of Care In Progressed Nsclc ALK+ Patients Based On RealWorld Evidence (RWE) And Clinical Trial Data In The Czech Republic Pasztor B1, Losenicky L2, Mazan P2, Duba J1, Kolek M1 Consulting s.r.o., Prague 9, Czech Republic, 2Pfizer PFE, spol. s r.o., Prague 5, Czech Republic
Bharmal M1, Guenther S1, Rosen G2, Kearney M1, Phatak H2, Kempel-Waibel A1 1Merck KGaA, Darmstadt, Germany, 2EMD Serono, Billerica, MA, USA
1OAKS
Objectives: Conduct a systematic literature review (SLR) of studies assessing clinical outcomes associated with pharmacological interventions in patients with locally advanced or metastatic urothelial cancer (UC) who have progressed during or after first line platinum-based chemotherapy. Methods: Medline, EMBASE, and conference proceedings databases were searched (2001 – 2017) to capture overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS) of systemic second-line therapy. 244 articles met the predefined inclusion criteria. Review of the 76 articles relating to second-line resulted in final data extraction from four randomized controlled clinical trials (RCTs) and thirty-eight single arm studies. Results: ORR with cisplatin- and carboplatin-based regimens, vinflunine, and immuno-oncology therapies (IOs) (either single or combination regimens) ranged from 8% to 50% in RCTs and from 6% to 60% in single arm studies. Median PFS with chemotherapy ranged from 3.3 to 4.0 months in RCTs (n= 2), from 1.4 to 6.0 (n= 15) in single arm studies, and from 1.1 to 4.1 (n= 5) with IOs. Median OS with chemotherapy ranged from 5.3 to 13.6 months (n= 23) and from 7.0 to 14.1 months (n= 7) with IOs (OS from many IO studies not estimated or reported due to limited follow up). Median DOR ranged from 3.9 to 9.1 months (n= 16) with chemotherapy regimens, and was not estimable in IO studies (n= 7), with > 80% of responders having responses lasting ≥ 6 months. Conclusions: There was a large variability in outcomes observed by regimen, patient population and study design. The findings of this SLR suggest a high unmet need still exists for patients who have failed or progressed after first-line treatment. This highlights the need for new treatment options that can induce durable responses in these patients. Recently approved IOs seem promising for a patient population with historically limited treatment options.
Objectives: Non-small-cell-lung-carcinoma (NSCLC) markedly shortens and deteriorates life of patients. The aim of this analysis was to compare the relative effectiveness of crizotinib in progressed NSCLC ALK+ patients to Czech standard of care based on RWE and clinical trial data while adjusting for patients’ characteristic differences. Methods: Patient characteristics and outcomes data were taken from RWE (NSCLC Registry TULUNG and Registry of Highly Innovative Drug VILP) in the Czech Republic and the PROFILE 1007 clinical trial. Patient-level data were available for crizotinib RWE only. Differences in patients’ characteristics in the crizotinib and pemetrexed arms were thus adjusted by MAIC approach. Age, sex, ECOG, smoking status, stage and histology types were included in the matching analysis. After matching, median overall survival (OS) and progression free survival (PFS) were estimated. Results: There were 51 crizotinib patients in the Czech RWE arm receiving 2nd or later line crizotinib. Median follow-up of crizotinib RWE patients was 11,5 months. After matching, the patients’ characteristics were comparable. Naïve comparison of PFS and OS resulted in medians 5,8 and 15,3 months for crizotinib from RWE, 3,1 and 9,5 months for pemetrexed from RWE and 4,2 and 22,8 for pemetrexed from PROFILE 1007. After matching, the median PFS and OS of crizotinib from RWE changed to 4,8 and 14,2 months when adjusted to pemetrexed RWE and 6,2 and 27,2 months when adjusted to pemetrexed PROFILE 1007 data. Crizotinib increased PFS by 54% and 47% and OS by 49% and 19% when compared to pemetrexed RWE and pemetrexed PROFILE 1007 data, respectively. Conclusions: Treatment of progressed ALK+ NSCLC with crizotinib is associated with major prolongation of PFS and OS compared to pemetrexed in the Czech real-world setting after adjusting for the patients’ characteristic differences.
PCN16 Comparative Study Of Healthcare Resource Utilization (HRU) Outcomes Between Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Versus Non-Ibrutinib Treated Patients Nero D1, Chung J1, Kish J1, Nabhan C2 1Cardinal Health Specialty Solutions, Dallas, TX, USA, 2Cardinal Health, Dublin, OH, USA
Objectives: Ibrutinib is a novel targeted oral therapy approved for CLL. We aimed to compare real-world HRU of ibrutinib-treated CLL patients with others not on ibrutinib. Methods: Newly diagnosed CLL patients initiating therapy between 01/01/2014-09/30/2016 were selected from the Inovalon Medical Outcomes Research
PCN19 Estimation of The Health Benefit Associated With A Potential Denosumab-Induced Extension of Progression Free Survival In Multiple Myeloma Patients Sabatelli L, Jamotte A, Giannopoulou C, Intorcia M Amgen GmbH, Zug, Switzerland
Objectives: The efficacy of Denosumab in the prevention of skeletal-related events in multiple myeloma (MM) patients, and its non-inferiority to Zoledronic Acid, was demonstrated in a randomized, double blind phase 3 trial (IMW 2017 and ASCO 2017). Preliminary analyses of trial survival data suggested that patients treated with Denosumab may have a longer progression free survival (PFS) compared to